Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)

Cardiovascular disease in patients with multiple myeloma may derive from factors unrelated to the disease (age, diabetes, dyslipidemia, obesity, prior cardiovascular diseases), related to the disease (cardiac AL-amyloidosis, hyperviscosity, high-output failure, arteriovenous shunting, anemia, renal...

Full description

Bibliographic Details
Published in:	Haematologica
Main Authors:	Sara Bringhen, Alberto Milan, Claudio Ferri, Ralph Wäsch, Francesca Gay, Alessandra Larocca, Marco Salvini, Evangelos Terpos, Hartmut Goldschmidt, Michele Cavo, Maria Teresa Petrucci, Heinz Ludwig, Holger W. Auner, Jo Caers, Martin Gramatzki, Mario Boccadoro, Hermann Einsele, Pieter Sonneveld, Monika Engelhardt
Format:	Article
Language:	English
Published:	Ferrata Storti Foundation 2018-09-01
Online Access:	https://haematologica.org/article/view/8581

Similar Items

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
by: Francesca Gay, et al.
Published: (2018-02-01)

European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
by: Jo Caers, et al.
Published: (2018-11-01)

P164 | REAL-WORLD APPROACHES TO VACCINATION AND ANTIMICROBIAL PROPHYLAXIS IN MULTIPLE MYELOMA: A SURVEY ACROSS EMN CENTERS
by: O. Annibali, et al.
Published: (2025-09-01)

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
by: Monika Engelhardt, et al.
Published: (2014-02-01)

Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN–HARMONY Alliance platform
by: Adrian Mosquera Orgueira, et al.
Published: (2025-10-01)

P872: EFFICACY OF DARATUMUMAB PLUS BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA PRESENTING WITH EXTRAMEDULLARY DISEASE: A EUROPEAN MYELOMA NETWORK STUDY (EMN19)
by: Meral Beksac, et al.
Published: (2023-08-01)

European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
by: Benedetto Bruno, et al.
Published: (2021-04-01)

2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde
by: Pellegrino Musto, et al.
Published: (2021-07-01)

European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications
by: Evangelos Terpos, et al.
Published: (2015-10-01)

Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial
by: Sara Bringhen, et al.
Published: (2020-07-01)

COVID-19 AND MYELOMA
by: H Ludwig, et al.
Published: (2022-04-01)

Autotransplants in older multiple myeloma patients: hype or hope in the era of novel agents?
by: Monika Engelhardt, et al.
Published: (2016-11-01)

In search for cure of multiple myeloma
by: Ralph Wäsch, et al.
Published: (2023-11-01)

Novel immunotherapies in multiple myeloma – chances and challenges
by: Leo Rasche, et al.
Published: (2021-07-01)

Carfilzomib combination treatment as first-line therapy in multiple myeloma: where do we go from the Carthadex (KTd)-trial update?
by: Monika Engelhardt, et al.
Published: (2019-11-01)

Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
by: Meletios A. Dimopoulos, et al.
Published: (2021-02-01)

Updated analysis of EMN02 demonstrated overall survival benefit to early ASCT for multiple myeloma
by: Alfred L. Garfall
Published: (2025-01-01)

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network
by: Philippe Moreau, et al.
Published: (2019-12-01)

Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network
by: Grigoris Gerotziafas, et al.
Published: (2025-08-01)

Prevention of bone disease and early detection of impending fractures in multiple myeloma patients can reduce morbidity and mortality: the necessity of interdisciplinary state-of-the-art treatment
by: Georg W. Herget, et al.
Published: (2020-04-01)

Age and aging in blood disorders: multiple myeloma
by: Sonja Zweegman, et al.
Published: (2014-07-01)

Proteasome inhibition: the dawn of novel therapies in multiple myeloma
by: Monika Engelhardt, et al.
Published: (2020-06-01)

European Myeloma Network Group Consensus Statement on the use of next‐generation sequencing for prognostic stratification of newly diagnosed multiple myeloma
by: Niccolò Bolli, et al.
Published: (2025-10-01)

A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients
by: Monika Engelhardt, et al.
Published: (2017-05-01)

Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible
by: Monika Engelhardt, et al.
Published: (2024-02-01)

Minimal residual disease detection in multiple myeloma: methods and prognostic significance
by: Evangelos Terpos
Published: (2020-10-01)

Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life
by: Christine Greil, et al.
Published: (2019-02-01)

Central nervous system myeloma: Pathogenesis, diagnostic challenges, and practical management strategies
by: Eirini Katodritou, et al.
Published: (2025-10-01)

Insights on Multiple Myeloma Treatment Strategies
by: María-Victoria Mateos, et al.
Published: (2019-02-01)

Analysis of skeletal pain, general symptoms and patient-reported outcome measures and their value in detecting symptomatic progression – An interdisciplinary prospective study in patients with multiple myeloma
by: Carlotta Pietsch, et al.
Published: (2025-06-01)

Moving Toward Continuous Therapy in Multiple Myeloma
by: Francesca Bonello, et al.
Published: (2019-11-01)

The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network
by: Niels W.C.J. van de Donk, et al.
Published: (2014-06-01)

Global myeloma research clusters, output, and citations: a bibliometric mapping and clustering analysis.
by: Jens Peter Andersen, et al.
Published: (2015-01-01)

Comorbidity indices for prognostic evaluation in multiple myeloma: a comprehensive evaluation of the Revised Myeloma Comorbidity Index and other comorbidity indices with pro- and retrospective applications
by: Katja Schoeller, et al.
Published: (2023-11-01)

Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel
by: Xavier Leleu, et al.
Published: (2023-02-01)

Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma
by: Maria Victoria Mateos, et al.
Published: (2024-02-01)

Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies
by: Simona Caltagirone, et al.
Published: (2014-10-01)

The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism
by: Gian Paolo Rossi, et al.
Published: (2020-06-01)

Vaccination Against SARS-CoV-2 for Myeloma Patients: Do We Need a Booster Dose and How Frequent?
by: Evangelos Terpos
Published: (2022-10-01)

Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores
by: Monika Engelhardt, et al.
Published: (2016-09-01)